Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones

Paul A. Dutchak, Takeshi Katafuchi, Angie L. Bookout, Jang Hyun Choi, Ruth T. Yu, David J. Mangelsdorf, Steven A. Kliewer

Research output: Contribution to journalArticle

319 Citations (Scopus)

Abstract

Fibroblast growth factor-21 (FGF21) is a circulating hepatokine that beneficially affects carbohydrate and lipid metabolism. Here, we report that FGF21 is also an inducible, fed-state autocrine factor in adipose tissue that functions in a feed-forward loop to regulate the activity of peroxisome proliferator-activated receptor γ (PPARγ), a master transcriptional regulator of adipogenesis. FGF21 knockout (KO) mice display defects in PPARγ signaling including decreased body fat and attenuation of PPARγ-dependent gene expression. Moreover, FGF21-KO mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight gain and edema side effects of the PPARγ agonist rosiglitazone. This loss of function in FGF21-KO mice is coincident with a marked increase in the sumoylation of PPARγ, which reduces its transcriptional activity. Adding back FGF21 prevents sumoylation and restores PPARγ activity. Collectively, these results reveal FGF21 as a key mediator of the physiologic and pharmacologic actions of PPARγ.

Original languageEnglish (US)
Pages (from-to)556-567
Number of pages12
JournalCell
Volume148
Issue number3
DOIs
StatePublished - Feb 3 2012

Fingerprint

Thiazolidinediones
Peroxisome Proliferator-Activated Receptors
Hypoglycemic Agents
Knockout Mice
Sumoylation
rosiglitazone
Adipose Tissue
Pharmacologic Actions
Adipogenesis
Carbohydrate Metabolism
fibroblast growth factor 21
Lipid Metabolism
Gene expression
Refractory materials
Weight Gain
Edema
Fats
Insulin
Tissue
Gene Expression

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. / Dutchak, Paul A.; Katafuchi, Takeshi; Bookout, Angie L.; Choi, Jang Hyun; Yu, Ruth T.; Mangelsdorf, David J.; Kliewer, Steven A.

In: Cell, Vol. 148, No. 3, 03.02.2012, p. 556-567.

Research output: Contribution to journalArticle

Dutchak, Paul A. ; Katafuchi, Takeshi ; Bookout, Angie L. ; Choi, Jang Hyun ; Yu, Ruth T. ; Mangelsdorf, David J. ; Kliewer, Steven A. / Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. In: Cell. 2012 ; Vol. 148, No. 3. pp. 556-567.
@article{3f1dc4c3fcb8458fb8dcaf29b390a0f0,
title = "Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones",
abstract = "Fibroblast growth factor-21 (FGF21) is a circulating hepatokine that beneficially affects carbohydrate and lipid metabolism. Here, we report that FGF21 is also an inducible, fed-state autocrine factor in adipose tissue that functions in a feed-forward loop to regulate the activity of peroxisome proliferator-activated receptor γ (PPARγ), a master transcriptional regulator of adipogenesis. FGF21 knockout (KO) mice display defects in PPARγ signaling including decreased body fat and attenuation of PPARγ-dependent gene expression. Moreover, FGF21-KO mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight gain and edema side effects of the PPARγ agonist rosiglitazone. This loss of function in FGF21-KO mice is coincident with a marked increase in the sumoylation of PPARγ, which reduces its transcriptional activity. Adding back FGF21 prevents sumoylation and restores PPARγ activity. Collectively, these results reveal FGF21 as a key mediator of the physiologic and pharmacologic actions of PPARγ.",
author = "Dutchak, {Paul A.} and Takeshi Katafuchi and Bookout, {Angie L.} and Choi, {Jang Hyun} and Yu, {Ruth T.} and Mangelsdorf, {David J.} and Kliewer, {Steven A.}",
year = "2012",
month = "2",
day = "3",
doi = "10.1016/j.cell.2011.11.062",
language = "English (US)",
volume = "148",
pages = "556--567",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones

AU - Dutchak, Paul A.

AU - Katafuchi, Takeshi

AU - Bookout, Angie L.

AU - Choi, Jang Hyun

AU - Yu, Ruth T.

AU - Mangelsdorf, David J.

AU - Kliewer, Steven A.

PY - 2012/2/3

Y1 - 2012/2/3

N2 - Fibroblast growth factor-21 (FGF21) is a circulating hepatokine that beneficially affects carbohydrate and lipid metabolism. Here, we report that FGF21 is also an inducible, fed-state autocrine factor in adipose tissue that functions in a feed-forward loop to regulate the activity of peroxisome proliferator-activated receptor γ (PPARγ), a master transcriptional regulator of adipogenesis. FGF21 knockout (KO) mice display defects in PPARγ signaling including decreased body fat and attenuation of PPARγ-dependent gene expression. Moreover, FGF21-KO mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight gain and edema side effects of the PPARγ agonist rosiglitazone. This loss of function in FGF21-KO mice is coincident with a marked increase in the sumoylation of PPARγ, which reduces its transcriptional activity. Adding back FGF21 prevents sumoylation and restores PPARγ activity. Collectively, these results reveal FGF21 as a key mediator of the physiologic and pharmacologic actions of PPARγ.

AB - Fibroblast growth factor-21 (FGF21) is a circulating hepatokine that beneficially affects carbohydrate and lipid metabolism. Here, we report that FGF21 is also an inducible, fed-state autocrine factor in adipose tissue that functions in a feed-forward loop to regulate the activity of peroxisome proliferator-activated receptor γ (PPARγ), a master transcriptional regulator of adipogenesis. FGF21 knockout (KO) mice display defects in PPARγ signaling including decreased body fat and attenuation of PPARγ-dependent gene expression. Moreover, FGF21-KO mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight gain and edema side effects of the PPARγ agonist rosiglitazone. This loss of function in FGF21-KO mice is coincident with a marked increase in the sumoylation of PPARγ, which reduces its transcriptional activity. Adding back FGF21 prevents sumoylation and restores PPARγ activity. Collectively, these results reveal FGF21 as a key mediator of the physiologic and pharmacologic actions of PPARγ.

UR - http://www.scopus.com/inward/record.url?scp=84863012459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863012459&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2011.11.062

DO - 10.1016/j.cell.2011.11.062

M3 - Article

VL - 148

SP - 556

EP - 567

JO - Cell

JF - Cell

SN - 0092-8674

IS - 3

ER -